Journal article
Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
The American heart journal, Vol.170(5), pp.865-871
11/2015
DOI: 10.1016/j.ahj.2015.08.002
PMID: 26542493
Abstract
Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines.
The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals.
The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction.
The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.
Details
- Title: Subtitle
- Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
- Creators
- Ann Marie Navar - Duke Clinical Research Institute, Durham, NC. Electronic address: navar006@mc.duke.eduTracy Y Wang - Duke Clinical Research Institute, Durham, NCAnne C Goldberg - Washington University School of Medicine, St Louis, MOJennifer G Robinson - University of Iowa, Iowa City, IAVeronique L Roger - Mayo Clinic, Rochester, MNPeter F Wilson - Emory Clinical Cardiovascular Institute, Atlanta, GASalim S Virani - Michael E. Debakey Veterans Affaris Hospital and Baylor College of Medicine, Houston, TXJoesph Elassal - Regeneron Pharmaceuticals, Inc, Tarrytown, NYL Veronica Lee - RegeneronLaura E Webb - Duke Clinical Research Institute, Durham, NCEric Peterson - Duke Clinical Research Institute, Durham, NC
- Resource Type
- Journal article
- Publication Details
- The American heart journal, Vol.170(5), pp.865-871
- Publisher
- United States
- DOI
- 10.1016/j.ahj.2015.08.002
- PMID
- 26542493
- ISSN
- 0002-8703
- eISSN
- 1097-6744
- Grant note
- DOI: 10.13039/100004339, name: Sanofi; DOI: 10.13039/100009857, name: Regeneron Pharmaceuticals
- Language
- English
- Date published
- 11/2015
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995060502771
Metrics
31 Record Views